Contemporary Presentation and Management of Valvular Heart Disease
Assistance Publique – Hôpitaux de Paris · Hôpital Bichat-Claude-Bernard · +30 more institutions
Abstract
Valvular heart disease (VHD) is an important cause of mortality and morbidity and has been subject to important changes in management. The VHD II survey was designed by the EURObservational Research Programme of the European Society of Cardiology to analyze actual management of VHD and to compare practice with guidelines.
Patients with severe native VHD or previous valvular intervention were enrolled prospectively across 28 countries over a 3-month period in 2017. Indications for intervention were considered concordant if the intervention was performed or scheduled in symptomatic patients, corresponding to Class I recommendations specified in the 2012 European Society of Cardiology and in the 2014 American Heart Association/American College of Cardiology VHD guidelines.
Citation impact
- FWCI
- 29.74
- Percentile
- 100%
- References
- 34
Authors
46Topics & keywords
- Medicine
- valvular heart disease
- Mitral regurgitation
- Interquartile range
- Stenosis
- Internal medicine
- Intervention (counseling)
- Cardiology
- Good health and well-being
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- BBayer
- SSanofi
- ELEdwards Lifesciences
- BSBoston Scientific Corporation
- SSymetis
- RResMed
- ULUniversiteit Leiden
- GRGedeon Richter
- LULeids Universitair Medisch Centrum
- SServier
- SJSt. Jude Medical
- NPNovartis Pharma
- AVAbbott Vascular
- DSDaiichi Sankyo Europe